1 / 23

RETROVIRUS RESEARCH CENTER

RETROVIRUS RESEARCH CENTER. CLINICAL, SOCIODEMOGRAPHIC AND IMMUNOLOGICAL PROFILE: BEFORE, DURING AND AFTER THE IMPLEMENTATION OF HAART THERAPY. Universidad Central del Caribe School of Medicine, University Hospital Ramon Ruiz Arnau Bayamon, Puerto Rico. Puerto Rico Health Regions.

ronny
Download Presentation

RETROVIRUS RESEARCH CENTER

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RETROVIRUS RESEARCH CENTER CLINICAL, SOCIODEMOGRAPHIC AND IMMUNOLOGICAL PROFILE: BEFORE, DURING AND AFTER THE IMPLEMENTATION OF HAART THERAPY. Universidad Central del Caribe School of Medicine, University Hospital Ramon Ruiz Arnau Bayamon, Puerto Rico

  2. Puerto Rico Health Regions

  3. Rationale • Retrovirus Research Center has been collecting data prospectively since 1992 • Availability of HAART began shortly after 1995 • Data on socio-demographic, clinical and immunological variables are available for study.

  4. Methods • Study Design: • A cross sectional study from a longitudinal cohort. • Setting: • The study group comes from the Bayamon area in the northern part of the island. Our health facilities serves eleven municipalities with a population of 660,440 inhabitants. • Study Group: • 3,151 HIV infected patients seen between 1992 through 2002.

  5. Methods • Variables: • Period of entry: (1992-1995, 1996-1998, 1999-2002) • Sociodemographic: age, gender. • HIV transmission mode and risk behaviors: IDU, heterosexual, MHSM, others • Clinical presentation (Stage of infection, patterns of chronic diseases, and profile of OI, medical therapy) • Immunological variables( CD4, CD8, HIV viral load • Survival analysis (time between AIDS diagnosis and last event (death or not death).

  6. Methods • Statistical Analyses: • Frequency, Percents, Mean, Median, SD, proportions, mortality rates. • Differences in proportions: Chi-Square, Fisher Exact test • Differences in mean: T-test for independent samples ANOVA. • Survival Analyses: Kaplan Meier procedure and Cox Model. • The overall significance level used was set to 0.05. • The statistical package used was SPSS 11.0 for Windows.

  7. Patient Flow Chart TOTAL (at December 2002) MALE 76% 72% 66% FEMALE 24% 28% 34% P=.0001

  8. Stage at Presentation Percent Years P=.0001

  9. AGE OF PATIENTS AT STUDY ENTRY Percent Years p<.0001

  10. Mean Age at Entry P<0.01

  11. AGE AND ENTRY WITH CLINICAL AIDS Percent Years P=.0001

  12. HIV RISK SCENARIO Percent P=.0001

  13. AIDS DEFINING CONDITIONS AS PER YEAR Percent of Patients <1996 1996-98 >1998 *p<.01

  14. PRESENCE OF CHRONIC CONDITIONS PERCENT OF PATIENTS <1996 1996-98 >1998 P<001

  15. USE OF ANTIRETROVIRAL THERAPY PERCENT OF PATIENTS ART <1996 1996-98 >1998 P<001

  16. Median Levels of CD4 Cell Count Per Year of Entry * P<.026

  17. Early MortalityMortality prior to last day of first interval Percent P<.0001

  18. MEDIAN OF SURVIVAL BY HIV/AIDS DIAGNOSIS

  19. Survival analysis within the HIV patientsdescribe by years of entry, n=982. P<.0001

  20. Survival analysis within the AIDS diagnosed patients describe by years of entry, n=2167. P< .0001

  21. CONCLUSIONS • INCREASED • FEMALES • HETEROSEXUAL BEHAVIOR AS RISK • AGE (OLDER PATIENTS IN PARTICULAR >55Y) • PATIENTS WITH IMMUNOLOGICAL AIDS AT ENTRY • CHRONIC CONDITIONS (DM,CV) • USE OF HAART INTERVENTION • MEDIAN SURVIVAL IN HIV AND AIDS

  22. CONCLUSIONS • DECREASED • IVU AS RISK FACTOR • CLINICAL AIDS AND HIV STAGE AT ENTRY • TOTAL CD4 CELL COUNT IN HIV AND AIDS • PCP, TOXO, TB AS INFECTIONS IN AIDS) • MORTALITY WITHIN SIX MONTHS OF ENTRY

  23. THANKS • INVESTIGATORS: • Robert Hunter Mellado, MD, FACP • María A. Gómez Escudero, Ph.D. • Diana M. Fernández Santos, MS, Ed.D. (candidate) • Angel M. Mayor Becerra, MD, MS • Eddy Ríos Olivares, Ph.D., MPH • José W. Rodríguez, Ph.D. • Carlos Leon Valiente, MD • Beatriz Martinez Ph.D. • Jose Rodriguez Ph.D. • Boukli Nawal Ph.D. • Data Analysts • Doris V. Báez Feliciano, MS • Alejandro Amill Rosario, MPH • Miriam Velázquez Díaz, MS • Data Abstractors • Gisela I. Cestero Salas, BA • Glenda L. Ortiz Torres, BA • Heidy Ortiz Marrero, BA • Data Entry • Wanda I. Marín Maldonado • Information Systems Specialist • Magaly Torres Talavera, BBA • Administrative Support • Lillian Santana Báez, BBA

More Related